QR-koodi

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

BACKGROUND: Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg BID (APV1200). METHODS: ESS40011 was a 24-week, multicenter, open-label, c...

Täydet tiedot

Tallennettuna:
Julkaisussa:BMC Infect Dis
Päätekijät: Nadler, Jeffrey P, Gathe, Joseph C, Pollard, Richard B, Richmond, Gary J, Liao, Qiming, Griffith, Sandy, Tracey Lancaster, C, Hernandez, Jaime E, Pappa, Keith A
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMC 2003
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165437/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12795812/
https://ncbi.nlm.nih.govhttps://doi.org/10.1186/1471-2334-3-10
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia